Cardiomyopathy in patients with type 1 tyrosinemia, and the effect of nitisinone treatment on cardiomyopathy
Öz
Purpose: This study aimed to retrospectively evaluate the frequency of cardiomyopathy and its response to routinely used nitisinone treatment in patients with tyrosinemia type 1.
Materials and Methods: Participants of this descriptive cross-sectional study were Tyrosinemia Type 1 patients who were under the care of a single metabolic unit. The primary outcome of the study was “presence of abnormal echocardiographic findings” at diagnosis and the impact of nitisinone treatment on the detected findings.
Results: Of the 54 patients enrolled in the study, 21 (38.9%) were female and 33 (61.1%) were male. 41 patients were evaluated using echocardiography at the time of diagnosis. 9 (21.9%) of them had hypertrophic cardiomyopathic alterations varying in severity. In the follow-up period, second echocardiographic examinations revealed improvements in cardiac alterations while on nitisinone treatment. Thirteen patients dropped out of follow-up. Of the remaining 41 patients, 10 (24.4%) patients died in the follow-up period, whereas 31 (75.6%) remained alive. Plasma aspartate aminotransferase (AST), total bilirubin, and direct bilirubin concentrations were significantly higher in patients witj normal cardiac evaluation.
Conclusion: Echocardiographic examination should be done in all tyrosinemia type 1 patients including those with an absence of cardiac manifestations. The presence of cardiomyopathy may indicate a poor prognosis. Nitisinone is found to have a positive impact on cardiomyopathy in patients with type 1 tyrosinemia.
Anahtar Kelimeler
Kaynakça
- 1. Stinton C, Geppert J, Freeman K, Clarke A, Johnson S, Fraser H, et al. Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy. Orphanet J Rare Dis. 2017 Mar;12(1):48.
- 2. Geppert J, Stinton C, Freeman K, Fraser H, Clarke A, Johnson S, et al. Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review. Orphanet J Rare Dis. 2017 Sep;12(1):154.
- 3. Chakrapani A, Gissen P, McKiernan P. Disorders of tyrosine metabolism. In: Inborn metabolic diseases. Springer; 2012. p. 265–76.
- 4. Chinsky JM, Singh R, Ficicioglu C, Van Karnebeek CDM, Grompe M, Mitchell G, et al. Diagnosis and treatment of Tyrosinemia Type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017;19(12):1380.
- 5. van Ginkel WG, Rodenburg IL, Harding CO, Hollak CEM, Heiner-Fokkema MR, van Spronsen FJ. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1. Paediatr Drugs. 2019 Dec;21(6):413–26.
- 6. van Vliet K, van Ginkel WG, Jahja R, Daly A, MacDonald A, De Laet C, et al. Emotional and behavioral problems, quality of life and metabolic control in Nitsinon-treated Tyrosinemia type 1 patients. Orphanet J Rare Dis. 2019 Dec;14(1):285.
- 7. Mohamed S, Kambal MA, Al Jurayyan NA, Al-Nemri A, Babiker A, Hasanato R, et al. Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy. BMC Res Notes. 2013 Sep;6:362.
- 8. Akdoğan M, Kayhan B, Diğdem Ö, Kacar S. Hereditary tyrosinemia presented by hepatocellular carcinoma in adult female patient: An unusual case report. Akad Gastroenteroloji Derg. 2007;6(2):90–3.
- 9. Aktuglu-Zeybek AC, Kiykim E, Cansever MS. Hereditary Tyrosinemia Type 1 in Turkey. Adv Exp Med Biol. 2017;959:157–72.
- 10. Arora N, Stumper O, Wright J, Kelly DA, McKiernan PJ. Cardiomyopathy in tyrosinaemia type I is common but usually benign. J Inherit Metab Dis. 2006 Feb;29(1):54–7.
